Abbott Laboratories reports $12.59 billion revenue for quarter ended June 30, 2026, up 13%

ยท ABT

Abbott Laboratories reported revenue of $12.59 billion for the quarter ended June 30, 2026, an increase of 13% from the same quarter a year earlier ($11.14 billion).

For the same period it posted net income of $928 million, down 47.8%, or $0.53 per diluted share (1.01 a year earlier).

That is a net margin of 7.4%.

On Sanad's AAOIFI Standard 21 screen, Abbott Laboratories is currently compliant: interest-bearing debt is 17.2% of market capitalisation (limit 30%), and impure income is 0.7% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on July 28, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Abbott Laboratories news